Lucid Diagnostics Inc. LUCD
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -163.28% | 48.31% | -40.94% | 15.96% | 59.66% |
| Total Depreciation and Amortization | 0.90% | 0.45% | -5.86% | 2.33% | -3.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 112.11% | -78.83% | 613.36% | -101.13% | -565.48% |
| Change in Net Operating Assets | 27.36% | -25.96% | -104.72% | -397.84% | 62.96% |
| Cash from Operations | -7.09% | 2.92% | -27.42% | -7.06% | 8.13% |
| Capital Expenditure | 16.00% | -131.18% | 80.31% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 16.00% | -131.18% | 80.31% | 92.00% | -- |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.35% | -63.50% | -- | 28,761.70% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.35% | -64.46% | -99.99% | 28,761.70% | 41.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.07% | -337.12% | -260.47% | 255.39% | 3,797.35% |